Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-01-16 pm EST			5-day change	1st Jan Change
108.83 ^USD	-1.93%		-1.54%	+3.39%

Jan. 16	Where the Money's Moving
Jan. 16	Some drugmakers quietly concerned about legal risk with speedy FDA review program	RE

Correction to Halozyme Granted Injunction Against Merck & Co. Article

Published on 12/04/2025 at 03:22 pm EST

Dow Jones

Merck & Co., Inc.

-1.93%

Halozyme Therapeutics, Inc.

-0.85%

Merck & Co. launched nullity proceedings against Halozyme's patent in German Federal Patent Court in August. "Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case," at 2:08 p.m. ET, incorrectly said Halozyme had launched nullity proceedings against Merck.

(END) Dow Jones Newswires

12-04-25 1521ET

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	MERCK & CO., INC.	108.83USD	-1.93%	-1.54%	270B
	HALOZYME THERAPEUTICS, INC.	71.21USD	-0.85%	-1.74%	8.37B

Latest news about Merck & Co., Inc.

Jan. 16	Where the Money's Moving
Jan. 16	Some drugmakers quietly concerned about legal risk with speedy FDA review program	RE
Jan. 15	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
Jan. 15	US FDA delays two drug reviews in new voucher program after safety, efficacy concerns	RE
Jan. 13	Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company	CI
Jan. 13	Illumina introduces Billion Cell Atlas, genome-wide genetic perturbation dataset	RE
Jan. 13	Illumina unveils dataset to speed up AI-powered drug discovery	RE
Jan. 13	Illumina Introduces Genetic Perturbation Dataset to Further AI Drug Discovery	MT
Jan. 13	The CPI That Changed Almost Nothing
Jan. 13	Global drugmakers rush to boost US presence as tariff threat looms	RE
Jan. 12	Merck & Co., Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 04:30 PM
Jan. 12	Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s	RE
Jan. 12	Moderna expects $1.9 billion in sales, trims costs forecast for 2025	RE
Jan. 09	Sector Update: Health Care Stocks Decline Late Afternoon	MT
Jan. 09	Sector Update: Health Care Stocks Mixed Friday Afternoon	MT
Jan. 09	Sector Update: Health Care	MT
Jan. 09	Top Midday Stories: December Jobs Data Undershoots Expectations; Meta Signs Nuclear Deals	MT
Jan. 09	Morgan Stanley Adjusts Price Target on Merck to $101 From $102, Maintains Equalweight Rating	MT
Jan. 09	Wall Street Gains Momentum Amid Jobs Report as US Equity Futures Edge Higher Pre-Bell	MT
Jan. 09	Morgan Stanley Trims Price Target on Merck to $101 From $102, Keeps Equalweight Rating	MT
Jan. 09	Merck reportedly consiering a major acquisition (Revolution Medicines)
Jan. 09	Merck Reportedly in Talks to Buy Revolution in Up to $32 Billion Deal	CI
Jan. 08	AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty	RE
Jan. 08	Merck & Co. in Talks to Acquire Revolution Medicines	MT
Jan. 08	Price tag of $28bn to $32bn was being discussed as part of Merck-Revolution Medicines deal - FT	RE

Chart Merck & Co., Inc.

Duration

Period

MRK: Dynamic Chart

Company Profile

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (20%); - sale of animal health products (9.2%); - other (1.4%). Net sales are distributed geographically as follows: the United States (50.3%), Europe/Middle East/Africa (21.8%), Latin America (5.4%), China (8.6%), Japan (5.1%), Asia/Pacific (4.8%) and other (4%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

Feb. 03 - Q4 2025 Earnings Release

More about the company